Advancing Osteoporosis Care in Canada: Insights on Biosimilars and Patient-Centered Switching

This discussion explores current challenges in osteoporosis care in Canada and shares real-world experience with transitioning patients from reference denosumab to biosimilars, highlighting patient acceptance, clinical workflows, and the importance of clear, efficient counseling. The conversation clarifies key distinctions between biosimilars and generics, examines clinical confidence supported by emerging evidence, and addresses how interchangeability, cost savings, and access considerations influence practice.

This video is sponsored by Sandoz.